提供者手术量对老年晚期卵巢癌患者一线化疗指南依从性及总生存的影响
基于SEER-Medicare数据库纳入1924例≥66岁FIGO II-IV期上皮性卵巢癌患者,比较不同提供者手术量三分位组间NCCN指南依从性(6周期铂类双药化疗)及生存差异。低手术量组指南依从率64.5%,中、高手术量组分别为72.2%和71.7%(p=.02);低手术量组中位OS 32.8个月,中、高手术量组分别为41.9和42.1个月(p<.01),校正病例组合后低手术量提供者与更高死亡率独立相关(aHR 1.25,95%CI 1.08,1.43)。
要点
- 低手术量提供者治疗的老年晚期EOC患者指南依从率更低(64.5% vs 72.2% vs 71.7%,p=.02)。
- 低手术量组中位OS 32.8个月,低于中、高手术量组的41.9和42.1个月(p<.01)。
- 校正病例组合后,低手术量提供者与更高死亡率独立相关(aHR 1.25,95%CI 1.08,1.43)。
核心结论
- 在当代老年Medicare晚期上皮性卵巢癌患者队列中,低手术量提供者治疗与更高比例的不依从治疗及更差生存相关。
- 作者认为需要紧急努力来解决这一手术量-结局差异。
研究设计与样本
- 查询SEER-Medicare数据库,纳入2004至2013年诊断的FIGO II-IV期上皮性卵巢癌、年龄≥66岁、接受手术并在诊断后7个月内接受化疗的患者。
- 共1924例患者符合纳入标准,按提供者手术量三分位分组比较NCCN指南依从性(6周期铂类双药化疗)及化疗相关毒性。
- 采用logistic回归评估与指南依从性及化疗相关毒性相关的因素,比较各手术量三分位组间总生存(OS),并建立Cox比例风险模型校正病例组合。
主要发现
- 总体指南依从率为70.3%,提供者手术量与依从性显著相关:低手术量组64.5%,中手术量组72.2%,高手术量组71.7%(p=.02)。
- 多因素模型中,低手术量提供者治疗和患者年龄≥80岁与更差的化疗指南依从性独立相关。
- 中位OS在各提供者手术量三分位组间存在显著差异:低手术量组32.8个月(95%CI 29.6,36.4),中手术量组41.9个月(95%CI 37.5,46.7),高手术量组42.1个月(95%CI 38.8,44.2)(p<.01)。
- 校正病例组合后,低手术量提供者与更高死亡率独立相关(aHR 1.25,95%CI 1.08,1.43)。
关键数值与推荐
- NCCN指南依从定义为6周期铂类双药化疗。
- 低手术量组指南依从率64.5%,中手术量组72.2%,高手术量组71.7%(p=.02)。
- 低手术量组中位OS 32.8个月(95%CI 29.6,36.4),中手术量组41.9个月(95%CI 37.5,46.7),高手术量组42.1个月(95%CI 38.8,44.2)(p<.01)。
- 低手术量提供者与更高死亡率独立相关(aHR 1.25,95%CI 1.08,1.43)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We sought to evaluate whether provider volume or other factors are associated with chemotherapy guideline compliance in elderly patients with epithelial ovarian cancer (EOC). METHODS: We queried the SEER-Medicare database for patients ≥66 years, diagnosed with FIGO stage II-IV EOC from 2004 to 2013 who underwent surgery and received chemotherapy within 7 months of diagnosis. We compared NCCN guideline compliance (6 cycles of platinum-based doublet) and chemotherapy-related toxicities across provider volume tertiles. Factors associated with guideline compliance and chemotherapy-related toxicities were assessed using logistic regression. Overall survival (OS) was compared across volume tertiles and Cox proportional-hazards model was created to adjust for case-mix. RESULTS: 1924 patients met inclusion criteria. The overall rate of guideline compliance was 70.3% with a significant association between provider volume and compliance (64.5% for low-volume, 72.2% for medium-volume, 71.7% for high-volume, p = .02). In the multivariate model, treatment by low-volume providers and patient age ≥ 80 years were independently associated with worse chemotherapy-guideline compliance. In the survival analysis, there was a significant difference in median OS across provider volume tertiles with median survival of 32.8 months (95%CI 29.6, 36.4) low-volume, 41.9 months (95%CI 37.5, 46.7) medium-volume, 42.1 months (95%CI 38.8, 44.2) high-volume providers, respectively (p < .01). After adjusting for case-mix, low-volume providers were independently associated with higher rates of mortality (aHR 1.25, 95%CI: 1.08, 1.43). CONCLUSIONS: In a modern cohort of elderly Medicare patients with advanced EOC, we found higher rates of non-compliant care and worse survival associated with treatment by low-volume Medicare providers. Urgent efforts are needed to address this volume-outcomes disparity.
引用
- Aviki EM, Lavery JA, Roche KL, et al. Impact of provider volume on front-line chemotherapy guideline compliance and overall survival in elderly patients with advanced ovarian cancer. Gynecol Oncol. 2020. PMID: 32814642. doi:10.1016/j.ygyno.2020.07.104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。